Interleukin-2 signaling and inherited immunodeficiency.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Therapy of 4T1 breast cancer in mice with Vaccinia virus encoding tumor-associated antigen epitopes and mouse IL2 cytokine.Frontiers in immunology · 2025
   Article
2. Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy.Frontiers in oncology · 2021
   Article
3. Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro.Bioengineering (Basel, Switzerland) · 2020
   Article
4. Prospects of IL-2 in Cancer Immunotherapy.BioMed research international · 2018
   Review
5. Regulation of Natural Killer Cell Function by STAT3.Frontiers in immunology · 2016
   Review
6. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells.Journal of immunology (Baltimore, Md. : 1950) · 2013
   Article
7. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma.Oncology letters · 2012
   Article
8. Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of gamma interferon.Infection and immunity · 2002
   Article
9. Targeting IL-2: an unexpected effect in treating immunological diseases.Signal transduction and targeted therapy
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as